

Criminal Code Regulations 2002

Statutory Rules No. 67, 2002

made under the

Criminal Code Act 1995

**Compilation No. 53**

**Compilation date:** 1 July 2017

**Includes amendments up to:** F2017L00843

**Registered:** 24 July 2017

**About this compilation**

**This compilation**

This is a compilation of the *Criminal Code Regulations 2002* that shows the text of the law as amended and in force on 1 July 2017 (the ***compilation date***).

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of provisions of the compiled law.

**Uncommenced amendments**

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Editorial changes**

For more information about any editorial changes made in this compilation, see the endnotes.

**Modifications**

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

**Self‑repealing provisions**

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

Contents

Part 1—Preliminary 1

1 Name of Regulations 1

3 Definitions 1

Part 2—Security of the Commonwealth 3

Division 1—Control orders 3

3A Legal representation for young people 3

3B Court may request legal aid commission to arrange representation 3

3C AFP to inform relevant persons of request and contact details 3

Division 2—Preventative detention orders 5

4 Preventative detention orders—corresponding State preventative detention law 5

Part 3—Dangers to the community 6

Division 1—Cross‑border firearms trafficking 6

5 Cross‑border firearms trafficking 6

Division 2—Serious drugs and precursors 7

5A Controlled drugs 7

5B Controlled plants 7

5C Controlled precursors 7

5D Border controlled drugs 8

5E Border controlled plants 8

5F Border controlled precursors 9

Division 3—Psychoactive substances 11

5G Importing psychoactive substances 11

5H Importing substances represented to be serious drug alternatives 12

Part 4—National infrastructure 14

6 Dangerous goods 14

Part 5—Application and transitional provisions 15

7 Application of the *Criminal Code Amendment (Control Orders—Legal Representation for Young People) Regulations 2017* 15

Schedule 1—Corresponding State preventative detention law 16

Part 1—Laws of a State or Territory 16

Part 2—Particular provisions of a law of a State or Territory 17

Schedule 2—Cross‑border firearms trafficking 18

Schedule 3—Controlled drugs 19

Schedule 4—Border controlled drugs 27

Endnotes 34

Endnote 1—About the endnotes 34

Endnote 2—Abbreviation key 35

Endnote 3—Legislation history 36

Endnote 4—Amendment history 40

Part 1—Preliminary

1 Name of Regulations

These Regulations are the *Criminal Code Regulations 2002*.

3 Definitions

In these Regulations:

***AFP member*** has the same meaning as in Part 5.3 of the Code.

***authorised person*** means a person authorised in writing by the Health Secretary to be an authorised person for the purposes of regulation 5 of the *Customs (Prohibited Imports) Regulations 1956*.

***chief executive officer*** of a legal aid commission of a State or Territory means the person holding, or performing the duties of, the following position:

(a) for New South Wales, Queensland and the Australian Capital Territory—Chief Executive Officer of the legal aid commission of that State or Territory;

(b) for Victoria—managing director of the board of directors of Victoria Legal Aid under the *Legal Aid Act 1978* (Vic);

(c) for Western Australia—Director of Legal Aid under the *Legal Aid Commission Act 1976* (WA);

(d) for South Australia—Director of Legal Services under the *Legal Services Commission Act 1977* (SA);

(e) for Tasmania—Director of the Commission under the *Legal Aid Commission Act 1990* (Tas.);

(f) for the Northern Territory—Director of Legal Aid under the *Legal Aid Act* (NT).

***Code*** means the *Criminal Code*.

***control order*** has the same meaning as in Part 5.3 of the Code.

***Health Department*** means the Department administered by the Health Minister.

***Health Minister*** means the Minister administering the *Therapeutic Goods Act 1989*.

***Health Secretary*** means the Secretary to the Health Department.

***issuing court*** has the same meaning as in Part 5.3 of the Code.

***lawyer*** has the same meaning as in Part 5.3 of the Code.

***legal aid commission*** means an authority established by or under a law of a State or Territory for the purpose of providing legal assistance.

***mental impairment*** has a meaning affected by subsections 7.3(8) and (9) of the Code.

***parent*** has a meaning affected by the Dictionary at the end of the Code.

Part 2—Security of the Commonwealth

Division 1—Control orders

3A Legal representation for young people

For the purposes of subsection 104.28(6) of the Code, this Division provides in relation to the appointing of a lawyer for a person who is at least 14 but under 18 (the ***young person***) to act for the young person in relation to proceedings relating to a control order.

3B Court may request legal aid commission to arrange representation

An issuing court may request a legal aid commission (the ***relevant legal aid commission***) to arrange the legal representation of the young person.

3C AFP to inform relevant persons of request and contact details

(1) This regulation applies if the issuing court decides to make a request under regulation 3B.

Informing the legal aid commission

(2) An AFP member, or a legal representative of the Australian Federal Police, must:

(a) in writing, inform the chief executive officer of the relevant legal aid commission of the request; and

(b) give the relevant legal aid commission the following information (if any) that the AFP member or legal representative has:

(i) the young person’s name;

(ii) the young person’s residential address;

(iii) the young person’s contact details, including a telephone number and an email address;

(iv) the young person’s date of birth;

(v) the name, residential address and contact details of at least one parent or guardian of the young person;

(vi) if the young person requires assistance with communication—information about the assistance required.

Note: For subparagraph (b)(vi), a person may need assistance with communication because, for example, the young person is deaf or hearing impaired, is unable to read, has a mental impairment, or requires an interpreter.

Informing the young person

(3) An AFP member must:

(a) inform the young person of the request; and

(b) give the young person sufficient information about the relevant legal aid commission to enable the young person to contact and, if necessary, attend the legal aid commission, including the following information (if any) that the AFP member has:

(i) the name of the legal aid commission;

(ii) the legal aid commission’s business address (not being a post box);

(iii) the legal aid commission’s contact details, including a telephone number and an email address;

(iv) any other information about the legal aid commission provided by the issuing court; and

(c) ensure that the young person understands the information provided to them under paragraphs (a) and (b) (taking into account the person’s age, language skills, mental capacity and any other relevant factor).

(4) Subregulation (3) does not apply if the actions of the young person make it impracticable for the AFP member to comply with that subregulation.

Informing a parent or guardian of the young person

(5) An AFP member must take reasonable steps to:

(a) inform at least one parent or guardian of the young person of the request; and

(b) give the parent or guardian the relevant legal aid commission’s contact details (including the details mentioned in paragraph (3)(b)).

(6) The AFP member or legal representative complying with subregulation (2), (3) or (5) must do so as soon as practicable after the issuing court decides to make the request and at least 48 hours before the next day when the court will conduct proceedings relating to the control order.

Division 2—Preventative detention orders

4 Preventative detention orders—corresponding State preventative detention law

(1) For the definition of ***corresponding State preventative detention law*** in subsection 100.1(1) of the Code, a law of a State or Territory that is set out in Part 1 of Schedule 1 is declared to correspond to Division 105 of the Code.

(2) For the definition of ***corresponding State preventative detention law*** in subsection 100.1(1) of the Code, particular provisions of a law of a State or Territory that are set out in Part 2 of Schedule 1 are declared to correspond to Division 105 of the Code.

Part 3—Dangers to the community

Division 1—Cross‑border firearms trafficking

5 Cross‑border firearms trafficking

For the definition of ***firearm law*** in subsections 360.2(3) and 360.3(2) of the Code, the Acts, and any regulations made under those Acts, mentioned in Schedule 2 are prescribed.

Division 2—Serious drugs and precursors

5A Controlled drugs

(1) For paragraph 301.1(1)(a) of the Code, a drug listed in column 1 of an item in Schedule 3 is a controlled drug.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity listed in column 2 of an item in Schedule 3 is the commercial quantity of the controlled drug listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity listed in column 3 of an item in Schedule 3 is the marketable quantity of the controlled drug listed in column 1 of that item.

(4) For paragraph (a) of item 1 of the table in section 301.12 of the Code, the quantity listed in column 4 of an item in Schedule 3 is the trafficable quantity of the controlled drug listed in column 1 of that item.

5B Controlled plants

(1) For paragraph 301.2(1)(a) of the Code, a growing plant listed in column 1 of an item in the following table is a controlled plant.

| Controlled plants and quantities | | | | |
| --- | --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 | Column 4 |
|  | Controlled plant | Commercial quantity | Marketable quantity | Trafficable quantity |
| 1 | Any plant of the genus *Cannabis* | 250 kg or 1,000 plants | 25 kg or 100 plants | 250 g or 10 plants |

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, a quantity listed in column 2 of an item in the table in subregulation (1) is a commercial quantity of the controlled plant listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, a quantity listed in column 3 of an item in the table in subregulation (1) is a marketable quantity of the controlled plant listed in column 1 of that item.

(4) For paragraph (a) of item 1 of the table in section 301.12 of the Code, a quantity listed in column 4 of an item in the table in subregulation (1) is the trafficable quantity of the controlled plant listed in column 1 of that item.

5C Controlled precursors

(1) For paragraph 301.3(1)(a) of the Code, a precursor listed in column 1 of an item in the following table is a controlled precursor.

| Controlled precursors and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Controlled precursor | Commercial quantity (kilograms) | Marketable quantity (grams) |
| 1 | Ephedrine | 1.2 | 400.0 |
| 2 | Ergometrine | 0.006 | 0.15 |
| 3 | Ergotamine | 0.01 | 0.25 |
| 4 | Isosafrole | 1.45 | 290.0 |
| 5 | Lysergic acid | 0.003 | 0.075 |
| 6 | 3,4‑Methylenedioxyphenylacetic acid | 1.5 | 300.0 |
| 7 | 3,4‑Methylenedioxyphenyl‑2‑propanone | 0.75 | 150.0 |
| 8 | Phenylacetic acid | 4.05 | 1,350.0 |
| 9 | Phenylpropanolamine | 1.2 | 400.0 |
| 10 | Phenyl‑2‑propanone | 2.03 | 675.0 |
| 11 | Piperonal | 1.6 | 320.0 |
| 12 | Pseudoephedrine | 1.2 | 400.0 |
| 13 | Safrole | 2.85 | 570.0 |

Note: A salt or ester of a precursor listed in column 1 of the table is also a controlled precursor: see paragraph 301.3(b) of the Code.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity listed in column 2 of an item in the table in subregulation (1) is the commercial quantity of the controlled precursor listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity listed in column 3 of an item in the table in subregulation (1) is the marketable quantity of the controlled precursor listed in column 1 of that item.

5D Border controlled drugs

(1) For paragraph 301.4(a) of the Code, a drug listed in column 1 of an item in Schedule 4 is a border controlled drug.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity listed in column 2 of an item in Schedule 4 is the commercial quantity of the border controlled drug listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity listed in column 3 of an item in Schedule 4 is the marketable quantity of the border controlled drug listed in column 1 of that item.

5E Border controlled plants

(1) For paragraph 301.5(a) of the Code, a growing plant listed in column 1 of an item in the following table is a border controlled plant.

| Border controlled plants and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Border controlled plant | Commercial quantity | Marketable quantity |
| 1 | Any plant of the genus *Cannabis* | 250 kg or 1,000 plants | 25 kg or 100 plants |
| 2 | Any plant of the genus *Erythroxylon* (also known as Erythroxylum) from which cocaine can be extracted either directly or by chemical transformation |  | 80 kg |
| 3 | Any plant of the genus *Lophophora* |  |  |
| 4 | Any plant of the species *Papaver bracteatum* |  | 10 kg |
| 5 | Any plant of the species *Papaver somniferum* |  | 10 kg |
| 6 | Any plant of the species *Piptagenia peregrine* |  |  |
| 7 | Any plant of the species *Psilocybe* |  |  |

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, a quantity (if any) listed in column 2 of an item in the table in subregulation (1) is a commercial quantity of the border controlled plant listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, a quantity (if any) listed in column 3 of an item in the table in subregulation (1) is a marketable quantity of the border controlled plant listed in column 1 of that item.

5F Border controlled precursors

(1) For paragraph 301.6(1)(a) of the Code, a precursor listed in column 1 of an item in the following table is a border controlled precursor.

| Border controlled precursors and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Border controlled precursor | Commercial quantity (kilograms) | Marketable quantity (grams) |
| 1 | N‑Acetylanthranilic acid |  |  |
| 2 | Any plant of the species *Ephedra* |  |  |
| 3 | Ephedrine | 1.2 | 3.2 |
| 4 | Ergometrine | 0.006 | 0.006 |
| 5 | Ergotamine | 0.01 | 0.01 |
| 6 | Isosafrole | 1.45 | 1.45 |
| 7 | Lysergic acid | 0.003 | 0.003 |
| 8 | 3,4‑Methylenedioxyphenyl‑2‑propanone | 0.75 | 0.75 |
| 9 | Phenylacetic acid | 4.05 | 10.8 |
| 10 | Phenylpropanolamine | 1.2 | 3.2 |
| 11 | Phenyl‑2‑propanone | 2.03 | 5.4 |
| 12 | Piperonal | 1.6 | 1.6 |
| 13 | Pseudoephedrine | 1.2 | 3.2 |
| 14 | Safrole | 2.85 | 2.85 |

Note: A salt or ester of a precursor listed in column 1 of the table and an immediate precursor of a precursor listed in column 1 of the table is a border controlled precursor: see paragraphs 301.6(1)(b) and (c) of the Code.

(2) For paragraph (a) of item 1 of the table in section 301.10 of the Code, the quantity (if any) listed in column 2 of an item in the table in subregulation (1) is the commercial quantity of the border controlled precursor listed in column 1 of that item.

(3) For paragraph (a) of item 1 of the table in section 301.11 of the Code, the quantity (if any) listed in column 3 of an item in the table in subregulation (1) is the marketable quantity of the border controlled precursor listed in column 1 of that item.

Division 3—Psychoactive substances

5G Importing psychoactive substances

(1) For paragraph 320.2(2)(l) of the Code, a substance that is imported into Australia in accordance with the conditions set out in subregulation (2) is prescribed.

(2) For the purpose of subregulation (1), the conditions are that:

(a) the person importing the substance (the ***importer***) is the holder of a licence to import drugs granted by the Health Secretary or an authorised person under subregulation 5(5) of the *Customs (Prohibited Imports) Regulations 1956*; and

(b) the importer:

(i) is, or is employed by, a forensic laboratory and is importing the substance for the purposes of forensic analysis; or

(ii) is the Australian Federal Police, or a police force of a State or Territory, and is importing the substance for the purposes of law enforcement; or

(iii) is the Commissioner or a Deputy Commissioner of the Australian Federal Police, or is the head or deputy head (however described) of a police force of a State or Territory, and is importing the substance for the purposes of law enforcement; or

(iv) is, or is employed by, a medical research facility and is importing the substance for the purposes of medical research; or

(v) is, or is employed by, a scientific research facility and is importing the substance for the purposes of scientific research; or

(vi) is, or is employed by, an entity that imports drugs on behalf of a person or body mentioned in subparagraph (i), (ii), (iii), (iv) or (v), being a person or body that also holds a licence of a kind mentioned in paragraph (a), and is importing the substance at the written request of the person or body; and

(c) before the substance is imported, the importer gives the Health Secretary or an authorised person a written notice about the proposed importation that includes:

(i) the identity and amount of the substance being imported; and

(ii) the purpose of the importation; and

(iii) a 30‑day period during which the importation is likely to occur; and

(iv) the importer’s name and import licence number; and

(v) if subparagraph (b)(i), (iv), (v) or (vi) applies and the importer is employed by the body mentioned in the applicable subparagraph—the name of the importer’s employer; and

(vi) any other information required by the Health Secretary.

(3) For the purpose of paragraph (2)(c), the Health Secretary may determine:

(a) information to be included in a notice; and

(b) the way a notice may be given to the Health Secretary or an authorised person.

(4) In this regulation:

***drug*** has the same meaning as in subregulation 5(20) of the *Customs (Prohibited Imports) Regulations 1956*.

5H Importing substances represented to be serious drug alternatives

(1) For paragraph 320.3(3)(f) of the Code, a substance that is imported into Australia in accordance with the conditions set out in subregulation (2) is prescribed.

(2) For the purpose of subregulation (1), the conditions are that:

(a) the person importing the substance (the ***importer***) is the holder of a licence to import drugs granted by the Health Secretary or an authorised person under subregulation 5(5) of the *Customs (Prohibited Imports) Regulations 1956*; and

(b) the importer:

(i) is, or is employed by, a forensic laboratory and is importing the substance for the purposes of forensic analysis; or

(ii) is the Australian Federal Police, or a police force of a State or Territory, and is importing the substance for the purposes of law enforcement; or

(iii) is the Commissioner or a Deputy Commissioner of the Australian Federal Police, or is the head or deputy head (however described) of a police force of a State or Territory, and is importing the substance for the purposes of law enforcement; or

(iv) is, or is employed by, a medical research facility and is importing the substance for the purposes of medical research; or

(v) is, or is employed by, a scientific research facility and is importing the substance for the purposes of scientific research; or

(vi) is, or is employed by, an entity that imports drugs on behalf of a person or body mentioned in subparagraph (i), (ii), (iii), (iv) or (v), being a person or body that also holds a licence of a kind mentioned in paragraph (a), and is importing the substance at the written request of the person or body; and

(c) before the substance is imported, the importer gives the Health Secretary or an authorised person a written notice about the proposed importation that includes:

(i) the identity and amount of the substance being imported; and

(ii) the purpose of the importation; and

(iii) a 30‑day period during which the importation is likely to occur; and

(iv) the importer’s name and import licence number; and

(v) if subparagraph (b)(i), (iv), (v) or (vi) applies and the importer is employed by the body mentioned in the applicable subparagraph—the name of the importer’s employer; and

(vi) any other information required by the Health Secretary.

(3) For the purpose of paragraph (2)(c), the Health Secretary may determine:

(a) information to be included in a notice; and

(b) the way a notice may be given to the Health Secretary or an authorised person.

(4) In this regulation:

***drug*** has the same meaning as in subregulation 5(20) of the *Customs (Prohibited Imports) Regulations 1956*.

Part 4—National infrastructure

6 Dangerous goods

For subparagraph 471.15(1)(b)(ii) of the Code, the following substances and things must not, without exception, be carried by post:

(a) gas that is so toxic or corrosive to humans as to pose a hazard to health;

(b) a thermally unstable substance that is likely to undergo a strongly exothermic decomposition;

(c) a substance that ignites or self‑heats when in contact with air.

Part 5—Application and transitional provisions

7 Application of the *Criminal Code Amendment (Control Orders—Legal Representation for Young People) Regulations 2017*

(1) The amendments made by items 1 and 2 of Schedule 1 to the *Criminal Code Amendment (Control Orders—Legal Representation for Young People) Regulations 2017* apply in relation to the parts of a proceeding that occur after the commencement of that instrument if:

(a) the proceeding commenced before or after the commencement of that instrument; and

(b) the proceeding relates to a control order made on or after 30 November 2016; and

(c) the control order was, or is, requested (however described) on or after 30 November 2016.

(2) To avoid doubt, those amendments apply in accordance with subregulation (1) regardless of when the conduct to which that request relates occurred or occurs.

Note: The conduct may have occurred before or after 30 November 2016.

Schedule 1—Corresponding State preventative detention law

(regulation 4)

Part 1—Laws of a State or Territory

| Item | Declared laws |
| --- | --- |
| 1 | *Terrorism (Preventative Detention) Act 2005* (Qld) |
| 1A | *Terrorism (Preventative Detention) Act 2006* (WA) |
| 2 | *Terrorism (Preventative Detention) Act 2005* (SA) |
| 3 | *Terrorism (Preventative Detention) Act 2005* (Tas) |

Part 2—Particular provisions of a law of a State or Territory

| Item | Declared provisions |
| --- | --- |
| 1 | Part 2A, *Terrorism (Police Powers) Act 2002* (NSW) |
| 2 | Part 2A, **Terrorism (Community Protection) Act 2003** (Vic) |
| 3 | Part 2, *Terrorism (Extraordinary Temporary Powers) Act 2006* (ACT) |
| 4 | Part 2B, *Terrorism (Emergency Powers) Act* (NT) |

Schedule 2—Cross‑border firearms trafficking

(regulation 5)

| Item | Act |
| --- | --- |
| 1 | *Firearms Act 1996* (NSW) |
| 2 | **Firearms Act 1996** (Vic) |
| 3 | *Weapons Act 1990* (Qld) |
| 4 | *Firearms Act 1973* (WA) |
| 5 | Firearms Act 1977 (SA) |
| 6 | *Firearms Act 1996* (Tas) |
| 7 | *Firearms Act 1996* (ACT) |
| 8 | *Firearms Act 1997* (NT) |
| 9 | *Firearms Act 1997* (Norfolk Island) |

Schedule 3—Controlled drugs

Note: See regulation 5A.

| Controlled drugs and quantities | | | | |
| --- | --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 | Column 4 |
|  | Controlled drug | Commercial quantity (kilograms) | Marketable quantity (grams) | Trafficable quantity (grams) |
| 1 | Acetorphine | 2.0 | 250.0 | 2.0 |
| 2 | Acetyl‑alpha‑methylfentanyl | 0.005 | 2.5 | 0.005 |
| 3 | 4‑Acetoxy‑N, N‑dimethyltryptamine (4‑AcO‑DMT) | 2.0 | 250.0 | 2.0 |
| 4 | 4‑Acetoxy‑N‑methyl‑N‑ethyltryptamine (4‑AcO‑MET) | 2.0 | 250.0 | 2.0 |
| 5 | Acetylcodeine | 2.0 | 250.0 | 2.0 |
| 6 | Acetyldihydrocodeine | 2.0 | 250.0 | 2.0 |
| 7 | Acetylmethadol | 2.0 | 250.0 | 2.0 |
| 8 | Allylprodine | 2.0 | 250.0 | 2.0 |
| 9 | Alphacetylmethadol | 10.0 | 5,000.0 | 10.0 |
| 10 | Alphameprodine | 0.2 | 100.0 | 0.2 |
| 11 | Alphamethadol | 0.2 | 100.0 | 0.2 |
| 12 | alpha‑Methylfentanyl | 0.005 | 2.5 | 0.005 |
| 13 | alpha‑Methylthiofentanyl | 0.005 | 2.5 | 0.005 |
| 14 | alpha‑Pyrrolidinobutiophenone (α‑PBP) | 0.75 | 250.0 | 0.75 |
| 15 | alpha‑Pyrrolidinopropiophenone (α‑PPP) | 0.75 | 250.0 | 0.75 |
| 16 | alpha‑Pyrrolidinovalerophenone (α‑PVP) | 0.75 | 250.0 | 0.75 |
| 17 | Alphaprodine | 25.0 | 12,500.0 | 25.0 |
| 18 | 5‑(2‑Aminopropyl)‑2,3‑dihydro‑1h‑indene (5‑APDI) | 0.75 | 250.0 | 0.75 |
| 19 | 6‑(2‑Aminopropyl)‑2,3‑dihydrobenzofuran (6‑APDB) | 0.75 | 250.0 | 0.75 |
| 20 | Amphetamine | 0.75 | 250.0 | 2.0 |
| 21 | Anileridine | 25.0 | 12,500.0 | 25.0 |
| 22 | Barbiturates | 5.0 |  | 5.0 |
| 23 | Benzethidine | 10.0 | 5,000.0 | 10.0 |
| 24 | 1‑(Benzofuran‑6‑yl) propan‑2‑amine (6‑APB) | 0.75 | 250.0 | 0.75 |
| 25 | Benzoylecgonine | 2.0 | 250.0 | 2.0 |
| 26 | Benzylmorphine | 5.0 | 2,500.0 | 5.0 |
| 27 | Benzylpiperazine | 0.75 | 250.0 | 2.0 |
| 28 | Betacetylmethadol | 5.0 | 2,500.0 | 5.0 |
| 29 | beta‑Hydroxyfentanyl | 0.005 | 2.5 | 0.005 |
| 30 | beta‑Hydroxy‑3‑methylfentanyl | 0.005 | 2.5 | 0.005 |
| 31 | beta‑Keto‑methylbenzodioxolylpentanamine (pentylone) | 0.75 | 250.0 | 0.75 |
| 32 | beta‑Keto‑N‑methyl‑3,4‑benzodioxyolylbutanamine (butylone) | 0.75 | 250.0 | 0.75 |
| 33 | Betameprodine | 5.0 | 2,500.0 | 5.0 |
| 34 | Betamethadol | 5.0 | 2,500.0 | 5.0 |
| 35 | Betaprodine | 5.0 | 2,500.0 | 5.0 |
| 36 | Bezitramide | 5.0 | 2,500.0 | 5.0 |
| 37 | 2‑Bromoamphetamine | 0.75 | 250.0 | 0.75 |
| 38 | 3‑Bromoamphetamine | 0.75 | 250.0 | 0.75 |
| 39 | 4‑Bromoamphetamine | 0.75 | 250.0 | 0.75 |
| 40 | 4‑Bromo‑2,5‑dimethoxyamphetamine | 0.5 | 100.0 | 0.5 |
| 41 | 2‑Bromo‑5‑methoxymethcathinone | 0.75 | 250.0 | 0.75 |
| 42 | 2‑Bromomethamphetamine | 0.75 | 250.0 | 0.75 |
| 43 | 3‑Bromomethamphetamine | 0.75 | 250.0 | 0.75 |
| 44 | 4‑Bromomethamphetamine | 0.75 | 250.0 | 0.75 |
| 45 | 2‑Bromomethcathinone | 0.75 | 250.0 | 0.75 |
| 46 | 3‑Bromomethcathinone | 0.75 | 250.0 | 0.75 |
| 47 | 4‑Bromomethcathinone | 0.75 | 250.0 | 0.75 |
| 48 | Bufotenine | 2.0 | 250.0 | 2.0 |
| 49 | Bupropion | 0.75 | 250.0 | 0.75 |
| 50 | Cannabis (in any form, including flowering or fruiting tops, leaves, seeds or stalks, but not including Cannabis resin or Cannabis fibre) | 125.0 | 25,000.0 | 250.0 |
| 51 | Cannabis resin | 125.0 | 25,000.0 | 20.0 |
| 52 | Cathinone | 0.75 | 250.0 | 0.75 |
| 53 | 1‑(4‑Chloro‑2,5‑dimethoxyphenyl)‑2‑ethenamine (2C‑C) | 0.5 | 100.0 | 0.5 |
| 54 | 2‑Chloroamphetamine | 0.75 | 250.0 | 0.75 |
| 55 | 3‑Chloroamphetamine | 0.75 | 250.0 | 0.75 |
| 56 | 4‑Chloroamphetamine | 0.75 | 250.0 | 0.75 |
| 57 | 2‑Chloromethamphetamine | 0.75 | 250.0 | 0.75 |
| 58 | 3‑Chloromethamphetamine | 0.75 | 250.0 | 0.75 |
| 59 | 4‑Chloromethamphetamine | 0.75 | 250.0 | 0.75 |
| 60 | 4‑Chloro‑N‑ethylamphetamine | 0.75 | 250.0 | 0.75 |
| 61 | 2‑Chloromethcathinone | 0.75 | 250.0 | 0.75 |
| 62 | 3‑Chloromethcathinone | 0.75 | 250.0 | 0.75 |
| 63 | 4‑Chloromethcathinone | 0.75 | 250.0 | 0.75 |
| 64 | 4‑Chlorophenyl‑1‑methoxypropan‑2‑amine | 0.75 | 250.0 | 0.75 |
| 65 | Chlorphentermine | 2.0 | 250.0 | 2.0 |
| 66 | Clonitazene | 5.0 | 100.0 | 5.0 |
| 67 | Cocaine | 2.0 | 250.0 | 2.0 |
| 68 | Codeine | 10.0 | 5,000.0 | 10.0 |
| 69 | Codeine‑N‑oxide | 10.0 | 5,000.0 | 10.0 |
| 70 | Codoxime | 10.0 | 5,000.0 | 10.0 |
| 71 | Desomorphine | 2.0 | 250.0 | 2.0 |
| 72 | Dexamphetamine | 2.0 | 250.0 | 2.0 |
| 73 | Dextromoramide | 2.0 | 250.0 | 2.0 |
| 74 | Diampromide | 5.0 | 2,500.0 | 5.0 |
| 75 | Diethylpropion (N, N‑Diethylcathinone) | 5.0 | 2,500.0 | 5.0 |
| 76 | Diethylthiambutene | 5.0 | 2,500.0 | 5.0 |
| 77 | N,N‑Diethyltryptamine | 2.0 | 250.0 | 2.0 |
| 78 | Difenoxin | 2.0 | 250.0 | 2.0 |
| 79 | 1‑(2,3‑Dihydro‑1‑benzofuran‑5‑yl)propan‑2‑amine (5‑APDB) | 0.75 | 250.0 | 0.75 |
| 80 | Dihydrocodeine | 10.0 | 5,000.0 | 10.0 |
| 81 | Dihydromorphine | 10.0 | 5,000.0 | 10.0 |
| 82 | Dimenoxadol | 10.0 | 5,000.0 | 10.0 |
| 83 | Dimepheptanol | 10.0 | 5,000.0 | 10.0 |
| 84 | 2,5‑Dimethoxy‑4‑bromophenethylamine (2C‑B) | 0.5 | 100.0 | 0.5 |
| 85 | 2,5‑Dimethoxy‑4‑ethylphenethylamine (2C‑E) | 0.5 | 100.0 | 0.5 |
| 86 | 2,5‑Dimethoxy‑4‑iodophenethylamine (2C‑I) | 0.5 | 100.0 | 0.5 |
| 87 | 2,5‑Dimethoxy‑4‑methylamphetamine (STP, DOM) | 0.75 | 250 | 0.75 |
| 88 | 2,5‑Dimethoxy‑4‑methylphenethylamine (2C‑D) | 0.5 | 100.0 | 0.5 |
| 89 | 2,5‑Dimethoxy‑4‑nitrophenethylamine (2C‑N) | 0.5 | 100.0 | 0.5 |
| 90 | 2,5‑Dimethoxy‑4‑(n)‑propylphenethylamine (2C‑P) | 0.5 | 100.0 | 0.5 |
| 91 | 3,4‑Dimethoxymethcathinone | 0.75 | 250.0 | 0.75 |
| 92 | 1‑Dimethylamino‑1,2‑diphenylethane | 5.0 | 2,500.0 | 5.0 |
| 93 | N,N‑Dimethylamphetamine | 0.75 | 250.0 | 0.75 |
| 94 | N, N‑Dimethylcathinone | 0.75 | 250.0 | 0.75 |
| 95 | 1,1‑Dimethylheptyl‑11‑hydroxytetrahydrocannabinol (HU‑210) | 5.0 | 1,000.0 | 5.0 |
| 96 | 3,4‑Dimethylmethcathinone | 0.75 | 250.0 | 0.75 |
| 97 | Dimethylthiambutene | 20.0 | 10,000.0 | 20.0 |
| 98 | N,N‑Dimethyltryptamine | 2.0 | 250.0 | 2.0 |
| 99 | Dioxaphetyl butyrate | 2.0 | 250.0 | 2.0 |
| 100 | Diphenoxylate | 2.0 | 250.0 | 2.0 |
| 101 | Dipipanone | 10.0 | 5,000.0 | 10.0 |
| 102 | Drotebanol | 2.0 | 250.0 | 2.0 |
| 103 | Ecgonine | 10.0 | 5,000.0 | 10.0 |
| 104 | Ethchlorvynol | 50.0 |  | 50.0 |
| 105 | Ethinamate | 50.0 |  | 50.0 |
| 106 | N‑Ethylcathinone | 0.75 | 250.0 | 0.75 |
| 107 | Ethylmethylthiambutene | 10.0 | 5,000.0 | 10.0 |
| 108 | Ethylmorphine | 2.0 | 250.0 | 2.0 |
| 109 | 3‑(2‑Ethylphenyl)‑2‑methyl‑quinazolin‑4‑one (Etaqualone) | 5.0 |  | 5.0 |
| 110 | Etonitazene | 5.0 | 2,500.0 | 5.0 |
| 111 | Etorphine | 5.0 | 2,500.0 | 5.0 |
| 112 | Etoxeridine | 5.0 | 2,500.0 | 5.0 |
| 113 | Fentanyl | 0.005 | 2.5 | 0.005 |
| 114 | 4‑Fluoro‑2,5‑dimethoxyphenethylamine (2C‑F) | 0.5 | 100.0 | 0.5 |
| 115 | 2‑Fluoroamphetamine | 0.75 | 250.0 | 0.75 |
| 116 | 3‑Fluoroamphetamine | 0.75 | 250.0 | 0.75 |
| 117 | 4‑Fluoroamphetamine | 0.75 | 250.0 | 0.75 |
| 118 | 2‑Fluoromethamphetamine | 0.75 | 250.0 | 0.75 |
| 119 | 3‑Fluoromethamphetamine | 0.75 | 250.0 | 0.75 |
| 120 | 4‑Fluoromethamphetamine | 0.75 | 250.0 | 0.75 |
| 121 | 2‑Fluoromethcathinone | 0.75 | 250.0 | 0.75 |
| 122 | 3‑Fluoromethcathinone | 0.75 | 250.0 | 0.75 |
| 123 | 4‑Fluoromethcathinone | 0.75 | 250.0 | 0.75 |
| 124 | Furethidine | 1.0 | 500.0 | 1.0 |
| 125 | Gammabutyrolactone (GBL) | 1.0 | 250.0 | 0.5 |
| 126 | Glutethimide | 50.0 |  | 50.0 |
| 127 | Heroin (diacetylmorphine) | 1.5 | 250.0 | 2.0 |
| 128 | Hydrocodone | 2.0 | 250.0 | 2.0 |
| 129 | Hydromorphinol | 2.0 | 250.0 | 2.0 |
| 130 | Hydromorphone | 2.0 | 250.0 | 2.0 |
| 131 | Hydroxyamphetamine | 2.0 | 250.0 | 2.0 |
| 132 | 4‑Hydroxybutanoic acid (GHB) | 1.0 | 250.0 | 0.5 |
| 133 | p‑Hydroxyephedrine | 2.0 | 250.0 | 2.0 |
| 134 | Hydroxypethidine | 0.75 | 250.0 | 0.75 |
| 135 | 2‑Iodoamphetamine | 0.75 | 250.0 | 0.75 |
| 136 | 3‑Iodoamphetamine | 0.75 | 250.0 | 0.75 |
| 137 | 4‑Iodoamphetamine | 0.75 | 250.0 | 0.75 |
| 138 | 2‑Iodomethamphetamine | 0.75 | 250.0 | 0.75 |
| 139 | 3‑Iodomethamphetamine | 0.75 | 250.0 | 0.75 |
| 140 | 4‑Iodomethamphetamine | 0.75 | 250.0 | 0.75 |
| 141 | 2‑Iodomethcathinone | 0.75 | 250.0 | 0.75 |
| 142 | 3‑Iodomethcathinone | 0.75 | 250.0 | 0.75 |
| 143 | 4‑Iodomethcathinone | 0.75 | 250.0 | 0.75 |
| 144 | Isomethadone | 2.0 | 250.0 | 2.0 |
| 145 | 4‑Isopropoxy‑2,5‑dimethoxyphenethylamine (2C‑O‑4) | 0.5 | 100.0 | 0.5 |
| 146 | Ketamine | 1.0 | 500.0 | 3.0 |
| 147 | Ketobemidone | 2.0 | 250.0 | 2.0 |
| 148 | Levophenacylmorphan | 2.0 | 250.0 | 2.0 |
| 149 | Levomethorphan | 2.0 | 250.0 | 2.0 |
| 150 | Levorphanol, but not including dextrorphan | 1.0 | 500.0 | 1.0 |
| 151 | Lysergamides | 0.01 |  | 0.01 |
| 152 | Lysergide (LSD) | 0.002 | 0.05 | 0.002 |
| 153 | Meprobamate | 50.0 |  | 50.0 |
| 154 | Mescaline | 7.5 | 3.75 | 7.5 |
| 155 | Metazocine | 7.0 | 3,500.0 | 7.0 |
| 156 | Methadone | 2.0 | 250.0 | 2.0 |
| 157 | Methamphetamine | 0.75 | 250.0 | 2.0 |
| 158 | Methaqualone | 5.0 |  | 5.0 |
| 159 | Methcathinone | 0.75 | 250.0 | 2.0 |
| 160 | Methorphan, but not including dextromethorphan | 2.0 | 250.0 | 2.0 |
| 161 | 4’‑Methoxy‑alpha‑pyrrolidinopropiophenone (MOPPP) | 0.75 | 250.0 | 0.75 |
| 162 | 4‑Methoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 163 | 4‑Methoxymethamphetamine | 0.75 | 250.0 | 0.75 |
| 164 | 4‑Methoxymethcathinone | 0.75 | 250.0 | 0.75 |
| 165 | 4’‑Methyl‑alpha‑pyrrolidinobutiophenone (MPBP) | 0.75 | 250.0 | 0.75 |
| 166 | 4’‑Methyl‑alpha‑pyrrolidinohexiophenone (MPHP) | 0.75 | 250.0 | 0.75 |
| 167 | 4’‑Methyl‑alpha‑pyrrolidinopropiophenone (MPPP) | 0.75 | 250.0 | 0.75 |
| 168 | N‑Methyl butylone | 0.75 | 250.0 | 0.75 |
| 169 | 2‑Methylamino‑1‑phenylbutan‑1‑ one (buphedrone) | 0.75 | 250.0 | 0.75 |
| 170 | 4‑Methylamphetamine | 0.75 | 250.0 | 0.75 |
| 171 | 3,4‑Methylenedioxyamphetamine (MDA) | 0.75 | 100.0 | 0.5 |
| 172 | 4‑Methylethcathinone | 0.75 | 250.0 | 0.75 |
| 173 | 3,4‑Methylenedioxymethamphetamine (MDMA) | 0.5 | 100.0 | 0.5 |
| 174 | Methyldesorphine | 2.0 | 250.0 | 2.0 |
| 175 | Methyldihydromorphine | 2.0 | 250.0 | 2.0 |
| 176 | 3,4‑Methylenedioxyethcathinone (MDEC) | 0.75 | 250.0 | 0.75 |
| 177 | 3,4‑Methylenedioxymethcathinone (MDMC) | 0.75 | 250.0 | 0.75 |
| 178 | 3,4‑Methylenedioxypyrovalerone (MDPV) | 0.75 | 250.0 | 0.75 |
| 179 | 3’,4’‑Methylenedioxy‑alpha‑pyrrolidinobutiophenone (MDPBP) | 0.75 | 250.0 | 0.75 |
| 180 | 3’,4’‑Methylenedioxy‑alpha‑pyrrolidinopropiophenone (MDPPP) | 0.75 | 250.0 | 0.75 |
| 181 | 3‑Methylfentanyl | 0.005 | 2.5 | 0.005 |
| 182 | 4‑Methylmethamphetamine | 0.75 | 250.0 | 0.75 |
| 183 | 4‑Methylmethcathinone (4‑MMC) | 0.75 | 250.0 | 2.0 |
| 184 | Methylphenidate | 2.0 | 250.0 | 2.0 |
| 185 | 1‑Methyl‑4‑phenyl‑4‑propionoxypiperidine (MPPP) | 2.0 | 250.0 | 2.0 |
| 186 | 4‑Methylthioamphetamine (4‑MTA) | 0.75 | 250.0 | 0.75 |
| 187 | 4‑Methylthiobutylamphetamine (4‑MTBA) | 0.75 | 250.0 | 0.75 |
| 188 | 4‑Methylthiodimethamphetamine (4‑MTDMA) | 0.75 | 250.0 | 0.75 |
| 189 | 4‑Methylthioethylamphetamine (4‑MTEA) | 0.75 | 250.0 | 0.75 |
| 190 | 3‑Methylthiofentanyl | 0.005 | 2.5 | 0.005 |
| 191 | 4‑Methylthiomethamphetamine (4‑MTMA) | 0.75 | 250.0 | 0.75 |
| 192 | 4‑Methylthiopropylamphetamine (4‑MTPA) | 0.75 | 250.0 | 0.75 |
| 193 | Methyprylon | 50.0 |  | 50.0 |
| 194 | Metopon | 2.0 | 250.0 | 2.0 |
| 195 | Monoacetylmorphines | 2.0 | 250.0 | 2.0 |
| 196 | Moramide | 2.0 | 250.0 | 2.0 |
| 197 | Morphan, but not including dextrorphan | 2.0 | 250.0 | 2.0 |
| 198 | Morpheridine | 2.0 | 250.0 | 2.0 |
| 199 | Morphine | 1.5 | 250.0 | 1.5 |
| 200 | Morphine‑N‑oxide | 2.0 | 250.0 | 2.0 |
| 201 | Myrophine | 20.0 |  | 20.0 |
| 202 | Nicocodine | 2.0 | 250.0 | 2.0 |
| 203 | Nicodicodine | 2.0 | 250.0 | 2.0 |
| 204 | Nicomorphine | 2.0 | 250.0 | 2.0 |
| 205 | Noracymethadol | 2.0 | 250.0 | 2.0 |
| 206 | Norcodeine | 2.0 | 250.0 | 2.0 |
| 207 | Norlevorphanol | 2.0 | 250.0 | 2.0 |
| 208 | Normethadone | 5.0 | 2,500.0 | 5.0 |
| 209 | Normorphine | 20.0 |  | 20.0 |
| 210 | Norpipanone | 10.0 | 5,000.0 | 10.0 |
| 211 | Opium | 20.0 | 10,000.0 | 20.0 |
| 212 | Oripavine | 2.0 | 250.0 | 2.0 |
| 213 | Oxycodone | 5.0 | 2,500.0 | 5.0 |
| 214 | Oxymorphone | 2.0 | 250.0 | 2.0 |
| 215 | para‑Fluorofentanyl | 0.005 | 2.5 | 0.005 |
| 216 | Pentazocine | 20.0 |  | 20.0 |
| 217 | Pethidine | 10.0 | 5,000.0 | 10.0 |
| 218 | Phenadoxone | 10.0 | 5,000.0 | 10.0 |
| 219 | Phenampromide | 10.0 | 5,000.0 | 10.0 |
| 220 | Phenazocine | 1.0 | 500.0 | 1.0 |
| 221 | Phencyclidine | 2.0 | 250.0 | 2.0 |
| 222 | Phendimetrazine | 5.0 | 2,500.0 | 5.0 |
| 223 | Phenmetrazine | 5.0 | 2,500.0 | 5.0 |
| 224 | Phenomorphan | 5.0 | 2,500.0 | 5.0 |
| 225 | Phenoperidine | 1.0 | 500.0 | 1.0 |
| 226 | Phentermine | 5.0 | 2,500.0 | 5.0 |
| 227 | 1‑Phenylethyl‑4‑phenyl‑4‑acetoxypiperidine (PEPAP) | 2.0 | 250.0 | 2.0 |
| 228 | Pholcodine | 5.0 | 2,500.0 | 5.0 |
| 229 | Piminodine | 10.0 | 5,000.0 | 10.0 |
| 230 | Pipradrol | 1.0 | 500.0 | 1.0 |
| 231 | Piritramide | 1.0 | 500.0 | 1.0 |
| 232 | Proheptazine | 1.0 | 500.0 | 1.0 |
| 233 | Properidine | 25.0 | 12,500.0 | 25.0 |
| 234 | Propiram | 10.0 | 5,000.0 | 10.0 |
| 235 | Psilocine | 2.0 | 1,000.0 | 2.0 |
| 236 | Psilocybine | 2.0 | 1,000.0 | 2.0 |
| 237 | Pyrovalerone | 0.75 | 250.0 | 0.75 |
| 238 | Tetrahydrocannabinols (THC) | 5.0 | 1,000.0 | 2.0 |
| 239 | Thebacon | 2.0 | 250.0 | 2.0 |
| 240 | Thebaine | 2.0 | 250.0 | 2.0 |
| 241 | Thiofentanyl | 0.005 | 2.5 | 0.005 |
| 242 | 2,4,5‑Trimethoxyphenethylamine (2C‑O) | 0.5 | 100.0 | 0.5 |
| 243 | Trimeperidine | 10.0 | 5,000.0 | 10.0 |
| 244 | 2,3,4‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 245 | 2,3,5‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 246 | 2,3,6‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 247 | 2,4,5‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 248 | 2,4,6‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |
| 249 | 3,4,5‑Trimethoxyamphetamine | 0.75 | 250.0 | 0.75 |

Note: A drug analogue of a drug listed in column 1 of the table is a controlled drug: see paragraph 301.1(b) of the Code.

Schedule 4—Border controlled drugs

Note: See regulation 5D.

| Border controlled drugs and quantities | | | |
| --- | --- | --- | --- |
| Item | Column 1 | Column 2 | Column 3 |
|  | Border controlled drug | Commercial quantity (kilograms) | Marketable quantity (grams) |
| 1 | Acetorphine | 2.0 | 2.0 |
| 2 | Acetyl‑alpha‑methylfentanyl | 0.005 | 0.005 |
| 3 | Acetylcodeine | 2.0 | 2.0 |
| 4 | Acetyldihydrocodeine | 2.0 | 2.0 |
| 5 | Acetylmethadol | 2.0 | 2.0 |
| 6 | Allylprodine | 2.0 | 2.0 |
| 7 | Alphacetylmethadol | 10.0 | 10.0 |
| 8 | Alphameprodine | 0.2 | 0.2 |
| 9 | Alphamethadol | 0.2 | 0.2 |
| 10 | alpha‑Methylfentanyl | 0.005 | 0.005 |
| 11 | alpha‑Methylthiofentanyl | 0.005 | 0.005 |
| 12 | Alphaprodine | 25.0 | 25.0 |
| 13 | Amphecloral | 2.0 | 2.0 |
| 14 | 3‑(2‑Aminopropyl)indole (alpha‑methyltryptamine (AMT)) | 2.0 | 2.0 |
| 15 | 5‑(2‑Aminopropyl)‑2,3‑dihydro‑1h‑indene (5‑APDI) | 0.75 | 0.5 |
| 16 | Amphetamine | 0.75 | 2.0 |
| 17 | Anileridine | 25.0 | 25.0 |
| 18 | Barbiturates | 5.0 | 50.0 |
| 19 | Benzethidine | 10.0 | 10.0 |
| 20 | 1‑(Benzofuran‑6‑yl) propan‑2‑amine (6‑APB) | 0.75 | 0.5 |
| 21 | Benzoylecgonine | 2.0 | 2.0 |
| 22 | Benzylmorphine | 5.0 | 5.0 |
| 23 | Benzylpiperazine | 0.75 | 2.0 |
| 24 | Betacetylmethadol | 5.0 | 5.0 |
| 25 | beta‑Hydroxyfentanyl | 0.005 | 0.005 |
| 26 | beta‑Hydroxy‑3‑methylfentanyl | 0.005 | 0.005 |
| 27 | beta‑Keto‑N‑methyl‑3,4‑benzodioxyolylbutanamine (butylone) | 0.75 | 2.0 |
| 28 | Betameprodine | 5.0 | 5.0 |
| 29 | Betamethadol | 5.0 | 5.0 |
| 30 | Betaprodine | 5.0 | 5.0 |
| 31 | Bezitramide | 5.0 | 5.0 |
| 32 | 4‑Bromo‑2,5‑dimethoxyamphetamine | 0.5 | 0.5 |
| 32A | 2‑(4‑bromo‑2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑B‑NBOMe) | 0.002 | 0.002 |
| 33 | Bufotenine | 2.0 | 2.0 |
| 34 | Cannabinoids (other than a Cannabinoid of a kind that can be obtained from a plant that is not a Cannabis plant) | 2.0 | 2.0 |
| 35 | Cannabis (in any form, including flowering or fruiting tops, leaves, seeds or stalks, but not including Cannabis resin or Cannabis fibre) | 100.0 | 25,000.0 |
| 36 | Cannabis resin | 50.0 | 20.0 |
| 37 | Cathinone | 0.75 | 2.0 |
| 38 | 1‑(4‑Chloro‑2,5‑dimethoxyphenyl)‑2‑ethenamine (2C‑C) | 0.5 | 0.5 |
| 38A | 2‑(4‑chloro‑2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑C‑NBOMe) | 0.002 | 0.002 |
| 39 | Chlorphentermine | 2.0 | 2.0 |
| 40 | Clonitazene | 5.0 | 5.0 |
| 41 | Cocaine | 2.0 | 2.0 |
| 42 | Codeine | 10.0 | 10.0 |
| 43 | Codeine‑N‑oxide | 10.0 | 10.0 |
| 44 | Codoxime | 10.0 | 10.0 |
| 45 | Desomorphine | 2.0 | 2.0 |
| 46 | Dexamphetamine | 2.0 | 2.0 |
| 47 | Dextromoramide | 2.0 | 2.0 |
| 48 | Diampromide | 5.0 | 5.0 |
| 49 | Diethylpropion (N, N‑Diethylcathinone) | 5.0 | 5.0 |
| 50 | Diethylthiambutene | 5.0 | 5.0 |
| 51 | N,N‑Diethyltryptamine | 2.0 | 2.0 |
| 52 | Difenoxin | 2.0 | 2.0 |
| 53 | Dihydrocodeine | 10.0 | 10.0 |
| 54 | Dihydromorphine | 10.0 | 10.0 |
| 55 | Dimenoxadol | 10.0 | 10.0 |
| 56 | Dimepheptanol | 10.0 | 10.0 |
| 57 | 2,5‑Dimethoxy‑4‑bromophenethylamine (2C‑B) | 0.5 | 0.5 |
| 58 | 2,5‑Dimethoxy‑4‑(n)‑butylthiophenethylamine (2C‑T‑9) | 0.5 | 0.5 |
| 59 | 2,5‑Dimethoxy‑4‑ethylphenethylamine (2C‑E) | 0.5 | 0.5 |
| 60 | 2,5‑Dimethoxy‑4‑ethylthiophenethylamine (2C‑T‑2) | 0.5 | 0.5 |
| 61 | 2,5‑Dimethoxy‑4‑iodophenethylamine (2C‑I) | 0.5 | 0.5 |
| 62 | 2,5‑Dimethoxy‑4‑(β‑isobutylthio)phenethylamine (2C‑T‑17) | 0.5 | 0.5 |
| 63 | 2,5‑Dimethoxy‑4‑isopropylthiophenethylamine (2C‑T‑4) | 0.5 | 0.5 |
| 64 | 2,5‑Dimethoxy‑4‑(β‑methoxyethylthio)phenethylamine (2C‑T‑13) | 0.5 | 0.5 |
| 65 | 2,5‑Dimethoxy‑4‑methylamphetamine (STP, DOM) | 0.75 | 2.0 |
| 66 | 2,5‑Dimethoxy‑4‑methylphenethylamine (2C‑D) | 0.5 | 0.5 |
| 67 | 2,5‑Dimethoxy‑4‑nitrophenethylamine (2C‑N) | 0.5 | 0.5 |
| 68 | 2,5‑Dimethoxy‑4‑(n)‑propylphenethylamine (2C‑P) | 0.5 | 0.5 |
| 69 | 2,5‑Dimethoxy‑4‑n‑propylthiophenethylamine (2C‑T‑7) | 0.5 | 0.5 |
| 69A | 2‑(2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑H‑NBOMe) | 0.002 | 0.002 |
| 70 | 1‑Dimethylamino‑1,2‑diphenylethane | 5.0 | 5.0 |
| 71 | 1,1‑Dimethylheptyl‑11‑hydroxytetrahydrocannabinol (HU‑210) | 5.0 | 2.0 |
| 72 | Dimethylthiambutene | 20.0 | 20.0 |
| 73 | N,N‑Dimethyltryptamine | 2.0 | 2.0 |
| 74 | Dioxaphetyl butyrate | 2.0 | 2.0 |
| 75 | Diphenoxylate | 2.0 | 2.0 |
| 76 | Dipipanone | 10.0 | 10.0 |
| 77 | Drotebanol | 2.0 | 2.0 |
| 78 | Ecgonine | 10.0 | 10.0 |
| 79 | Ethchlorvynol | 50.0 | 50.0 |
| 80 | Ethinamate | 50.0 | 50.0 |
| 81 | Ethylmethylthiambutene | 10.0 | 10.0 |
| 82 | Ethylmorphine | 2.0 | 2.0 |
| 83 | Etonitazene | 5.0 | 5.0 |
| 84 | Etorphine | 5.0 | 5.0 |
| 85 | Etoxeridine | 5.0 | 5.0 |
| 86 | Fentanyl | 0.005 | 0.005 |
| 87 | 4‑Fluoro‑2,5‑dimethoxyphenethylamine (2C‑F) | 0.5 | 0.5 |
| 88 | 4‑(2‑Fluoroethylthio)‑2,5‑dimethoxyphenethylamine (2C‑T‑21) | 0.5 | 0.5 |
| 89 | 1‑(5‑fluoropentyl)‑3‑(2‑iodobenzyl)indole (AM‑694) | 5.0 | 2.0 |
| 90 | Furethidine | 1.0 | 1.0 |
| 91 | Gammabutyrolactone (GBL) | 1.0 | 2.0 |
| 92 | Glutethimide | 50.0 | 50.0 |
| 93 | Harmaline | 5.0 | 2.0 |
| 94 | Harmine | 5.0 | 2.0 |
| 95 | Heroin (diacetylmorphine) | 1.5 | 2.0 |
| 96 | Hydrocodone | 2.0 | 2.0 |
| 97 | Hydromorphinol | 2.0 | 2.0 |
| 98 | Hydromorphone | 2.0 | 2.0 |
| 99 | Hydroxyamphetamine | 2.0 | 2.0 |
| 100 | 4‑Hydroxybutanoic acid (GHB) | 1.0 | 2.0 |
| 101 | 2‑[(1R,3S)‑3‑hydroxycyclohexyl]‑5‑(2‑methyloctan‑2‑yl)phenol (CP 47,497) | 5.0 | 2.0 |
| 102 | 2‑[(1R,3S)‑3‑hydroxycyclohexyl]‑5‑(2‑methylnonan‑2‑yl)phenol (CP 47,497‑C8) | 5.0 | 2.0 |
| 103 | Hydroxypethidine | 5.0 | 5.0 |
| 103A | 2‑(4‑iodo‑2,5‑dimethoxyphenyl)‑N‑[(2‑methoxyphenyl)methyl]ethanamine (25‑I‑NBOMe) | 0.002 | 0.002 |
| 104 | Isomethadone | 2.0 | 2.0 |
| 105 | 4‑Isopropoxy‑2,5‑dimethoxyphenethylamine (2C‑O‑4) | 0.5 | 0.5 |
| 106 | Ketamine | 1.0 | 3.0 |
| 107 | Ketobemidone | 2.0 | 2.0 |
| 108 | Levophenacylmorphan | 2.0 | 2.0 |
| 109 | Levomethorphan | 2.0 | 2.0 |
| 110 | Levorphanol, but not including dextrorphan | 1.0 | 1.0 |
| 111 | Lysergamide | 0.01 | 0.1 |
| 112 | Lysergide (LSD) | 0.002 | 0.002 |
| 113 | Meprobamate | 50.0 | 50.0 |
| 114 | Mescaline | 7.5 | 7.5 |
| 115 | Metazocine | 7.0 | 7.0 |
| 116 | Methadone | 2.0 | 2.0 |
| 117 | Methamphetamine | 0.75 | 2.0 |
| 118 | Methaqualone | 5.0 | 50.0 |
| 119 | Methcathinone | 0.75 | 2.0 |
| 120 | Methorphan, but not including dextromethorphan | 2.0 | 2.0 |
| 121 | 5‑Methoxy‑alpha‑methyltryptamine (5‑MeO‑AMT) | 2.0 | 2.0 |
| 122 | 5‑Methoxy‑N,N‑diisopropyltryptamine (5‑MeO‑DiPT) | 2.0 | 2.0 |
| 123 | 4‑Methoxyamphetamine | 0.75 | 2.0 |
| 124 | 4‑Methoxymethamphetamine | 0.75 | 2.0 |
| 125 | 4‑Methylamphetamine | 0.75 | 2.0 |
| 126 | 3,4‑Methylenedioxyamphetamine (MDA) | 0.75 | 0.5 |
| 127 | 2‑(2‑Methoxyphenyl)‑1‑(1‑pentylindol‑3‑yl)ethanone (JWH‑250) | 5.0 | 2.0 |
| 128 | 3,4‑Methylenedioxymethamphetamine (MDMA) | 0.5 | 0.5 |
| 129 | Methyldesorphine | 2.0 | 2.0 |
| 130 | Methyldihydromorphine | 2.0 | 2.0 |
| 131 | 3,4‑Methylenedioxypyrovalerone (MDPV) | 0.75 | 2.0 |
| 132 | 3‑Methylfentanyl | 0.005 | 0.005 |
| 133 | 4‑Methylmethamphetamine | 0.75 | 2.0 |
| 134 | 4‑Methylmethcathinone (4‑MMC) | 0.75 | 2.0 |
| 135 | Methylphenidate | 2.0 | 2.0 |
| 136 | 1‑Methyl‑4‑phenyl‑4‑propionoxypiperidine (MPPP) | 2.0 | 2.0 |
| 137 | 4‑Methylthio‑2,5‑dimethoxyphenethylamine (2C‑T) | 0.5 | 0.5 |
| 138 | 4‑Methylthioamphetamine (4‑MTA) | 0.75 | 2.0 |
| 139 | 4‑Methylthiobutylamphetamine (4‑MTBA) | 0.75 | 2.0 |
| 140 | 4‑Methylthiodimethamphetamine (4‑MTDMA) | 0.75 | 2.0 |
| 141 | 4‑Methylthioethylamphetamine (4‑MTEA) | 0.75 | 2.0 |
| 142 | 3‑Methylthiofentanyl | 0.005 | 0.005 |
| 143 | 4‑Methylthiomethamphetamine (4‑MTMA) | 0.75 | 2.0 |
| 144 | 4‑Methylthiopropylamphetamine (4‑MTPA) | 0.75 | 2.0 |
| 145 | Methyprylon | 50.0 | 50.0 |
| 146 | Metopon | 2.0 | 2.0 |
| 147 | Monoacetylmorphines | 2.0 | 2.0 |
| 148 | Moramide | 2.0 | 2.0 |
| 149 | Morphan, but not including dextrorphan | 2.0 | 2.0 |
| 150 | Morpheridine | 2.0 | 2.0 |
| 151 | Morphine | 1.5 | 2.0 |
| 152 | Morphine‑N‑oxide | 2.0 | 2.0 |
| 153 | (1‑(2‑Morpholin‑4‑ylethyl)indol‑3‑yl)‑napthalen‑1‑ylmethanone (JWH‑200) | 5.0 | 2.0 |
| 154 | Myrophine | 20.0 | 20.0 |
| 155 | Napthalen‑1‑yl‑(1‑butylindol‑3‑yl)methanone (JWH‑073) | 5.0 | 2.0 |
| 156 | Nicocodine | 2.0 | 2.0 |
| 157 | Nicodicodine | 2.0 | 2.0 |
| 158 | Nicomorphine | 2.0 | 2.0 |
| 159 | Noracymethadol | 2.0 | 2.0 |
| 160 | Norcodeine | 2.0 | 2.0 |
| 161 | Norlevorphanol | 2.0 | 2.0 |
| 162 | Normethadone | 5.0 | 5.0 |
| 163 | Normorphine | 20.0 | 20.0 |
| 164 | Norpipanone | 10.0 | 10.0 |
| 165 | Opium | 20.0 | 20.0 |
| 166 | Oripavine | 2.0 | 2.0 |
| 167 | Oxycodone | 5.0 | 5.0 |
| 168 | Oxymorphone | 2.0 | 2.0 |
| 169 | para‑Fluorofentanyl | 0.005 | 0.005 |
| 170 | Pentazocine | 20.0 | 20.0 |
| 171 | 1‑Pentyl‑3‑(1‑napthoyl)indol (JWH‑018) | 5.0 | 2.0 |
| 172 | Pethidine | 10.0 | 10.0 |
| 173 | 1‑Pentyl‑3‑(4‑methyl‑1‑napthoyl)indole (JWH‑122) | 5.0 | 2.0 |
| 174 | Phenadoxone | 10.0 | 10.0 |
| 175 | Phenampromide | 10.0 | 10.0 |
| 176 | Phenazocine | 1.0 | 1.0 |
| 177 | Phencyclidine | 2.0 | 2.0 |
| 178 | Phendimetrazine | 5.0 | 5.0 |
| 179 | Phenmetrazine | 5.0 | 5.0 |
| 180 | Phenomorphan | 5.0 | 5.0 |
| 181 | Phenoperidine | 1.0 | 1.0 |
| 182 | Phentermine | 5.0 | 5.0 |
| 183 | 1‑Phenylethyl‑4‑phenyl‑4‑acetoxypiperidine (PEPAP) | 2.0 | 2.0 |
| 184 | Pholcodine | 5.0 | 5.0 |
| 185 | Piminodine | 10.0 | 10.0 |
| 186 | Pipradrol | 1.0 | 1.0 |
| 187 | Piritramide | 1.0 | 1.0 |
| 188 | Proheptazine | 1.0 | 1.0 |
| 189 | Properidine | 25.0 | 25.0 |
| 190 | Propiram | 10.0 | 10.0 |
| 191 | Psilocine | 0.1 | 0.1 |
| 192 | Psilocybine | 0.1 | 0.1 |
| 193 | Pyrovalerone | 0.75 | 2.0 |
| 194 | Tetrahydrocannabinols (THC) | 5.0 | 2.0 |
| 195 | Thebacon | 2.0 | 2.0 |
| 196 | Thebaine | 2.0 | 2.0 |
| 197 | Thiofentanyl | 0.005 | 0.005 |
| 198 | 2,4,5‑Trimethoxyphenethylamine (2C‑O) | 0.5 | 0.5 |
| 199 | Trimeperidine | 10.0 | 10.0 |
| 200 | 2,3,4‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 201 | 2,3,5‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 202 | 2,3,6‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 203 | 2,4,5‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 204 | 2,4,6‑Trimethoxyamphetamine | 0.75 | 2.0 |
| 205 | 3,4,5‑Trimethoxyamphetamine | 0.75 | 2.0 |

Note: A drug analogue of a drug listed in column 1 of the table is a border controlled drug: see paragraph 301.4(b) of the Code.

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Editorial changes**

The *Legislation Act 2003* authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| ad = added or inserted | o = order(s) |
| am = amended | Ord = Ordinance |
| amdt = amendment | orig = original |
| c = clause(s) | par = paragraph(s)/subparagraph(s) |
| C[x] = Compilation No. x | /sub‑subparagraph(s) |
| Ch = Chapter(s) | pres = present |
| def = definition(s) | prev = previous |
| Dict = Dictionary | (prev…) = previously |
| disallowed = disallowed by Parliament | Pt = Part(s) |
| Div = Division(s) | r = regulation(s)/rule(s) |
| ed = editorial change | reloc = relocated |
| exp = expires/expired or ceases/ceased to have | renum = renumbered |
| effect | rep = repealed |
| F = Federal Register of Legislation | rs = repealed and substituted |
| gaz = gazette | s = section(s)/subsection(s) |
| LA = *Legislation Act 2003* | Sch = Schedule(s) |
| LIA = *Legislative Instruments Act 2003* | Sdiv = Subdivision(s) |
| (md) = misdescribed amendment can be given | SLI = Select Legislative Instrument |
| effect | SR = Statutory Rules |
| (md not incorp) = misdescribed amendment | Sub‑Ch = Sub‑Chapter(s) |
| cannot be given effect | SubPt = Subpart(s) |
| mod = modified/modification | underlining = whole or part not |
| No. = Number(s) | commenced or to be commenced |

Endnote 3—Legislation history

| Number and year | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| 67, 2002 | 12 Apr 2002 | 12 Apr 2002 |  |
| 248, 2002 | 21 Oct 2002 | 21 Oct 2002 | — |
| 249, 2002 | 21 Oct 2002 | 21 Oct 2002(r 2) | — |
| 250, 2002 | 27 Oct 2002 | 27 Oct 2002 | — |
| 269, 2002 | 14 Nov 2002 | 14 Nov 2002 | — |
| 270, 2002 | 14 Nov 2002 | 14 Nov 2002 | — |
| 271, 2002 | 14 Nov 2002 | 14 Nov 2002 | — |
| 272, 2002 | 14 Nov 2002 | 14 Nov 2002 | — |
| 30, 2003 | 7 Mar 2003 | 7 Mar 2003 | — |
| 43, 2003 | 27 Mar 2003 | 27 Mar 2003 | — |
| 59, 2003 | 11 Apr 2003 | 11 April 2003 | — |
| 60, 2003 | 11 Apr 2003 | 11 April 2003 | — |
| 61, 2003 | 11 Apr 2003 | 11 April 2003 | — |
| 62, 2003 | 11 Apr 2003 | 11 April 2003 | — |
| 63, 2003 | 11 Apr 2003 | 11 April 2003 | — |
| 64, 2003 | 11 Apr 2003 | 11 April 2003 | — |
| 184, 2003 | 18 July 2003 | 5 June 2003 | — |
| 285, 2003 | 9 Nov 2003 | 9 Nov 2003 | — |
| 83, 2004 | 3 May 2004 | 3 May 2004 | — |
| 283, 2004 | 1 Sept 2004 | 1 Sept 2004 | — |
| 284, 2004 | 1 Sept 2004 | 1 Sept 2004 | — |
| 311, 2004 | 5 Nov 2004 | 5 Nov 2004 | — |
| 312, 2004 | 5 Nov 2004 | 5 Nov 2004 | — |
| 313, 2004 | 5 Nov 2004 | 5 Nov 2004 | — |
| 314, 2004 | 5 Nov 2004 | 5 Nov 2004 | — |
| 23, 2005 | 1 Mar 2005 (F2005L00384) | 2 Mar 2005 | — |
| 36, 2005 | 23 Mar 2005 (F2005L00699) | 27 Mar 2005 | — |
| 57, 2005 | 8 Apr 2005 (F2005L00703) | 11 Apr 2005 | — |
| 58, 2005 | 8 Apr 2005 (F2005L00702) | 11 Apr 2005 | — |
| 59, 2005 | 8 Apr 2005 (F2005L00707) | 11 Apr 2005 | — |
| 60, 2005 | 8 Apr 2005 (F2005L00701) | 11 Apr 2005 | — |
| 61, 2005 | 8 Apr 2005 (F2005L00706) | 11 Apr 2005 | — |
| 62, 2005 | 8 Apr 2005 (F2005L00850) | 11 Apr 2005 | — |
| 85, 2005 | 26 May 2005 (F2005L01201) | 5 June 2005 | — |
| 86, 2005 | 26 May 2005 (F2005L01202) | 5 June 2005 | — |
| 287, 2005 | 26 May 2005 (F2005L01203) | 5 June 2005 | — |
| 88, 2005 | 26 May 2005 (F2005L01204) | 5 June 2005 | — |
| 214, 2005 | 6 Oct 2005 (F2005L02976) | 7 Oct 2005 | — |
| 298, 2005 | 16 Dec 2005 (F2005L04036) | 17 Dec 2005 | — |
| 178, 2006 | 14 July 2006 (F2006L01551) | 15 July 2006 | — |
| 220, 2006 | 25 Aug 2006 (F2006L02639) | 26 Aug 2006 | — |
| 221, 2006 | 25 Aug 2006 (F2006L02640) | 26 Aug 2006 | — |
| 276, 2006 | 2 Nov 2006 (F2006L03473) | 3 Nov 2006 | — |
| 277, 2006 | 2 Nov 2006 (F2006L03474) | 3 Nov 2006 | — |
| 278, 2006 | 2 Nov 2006 (F2006L03475) | 3 Nov 2006 | — |
| 279, 2006 | 2 Nov 2006 (F2006L03476) | 3 Nov 2006 | — |
| 280, 2006 | 2 Nov 2006 (F2006L03538) | 3 Nov 2006 | — |
| 3, 2007 | 16 Feb 2007 (F2007L00284) | 17 Feb 2007 | — |
| 39, 2007 | 23 Mar 2007 (F2007L00577) | 24 Mar 2007 | — |
| 47, 2007 | 30 Mar 2007 (F2007L00847) | 31 Mar 2007 | — |
| 48, 2007 | 30 Mar 2007 (F2007L00850) | 31 Mar 2007 | — |
| 49, 2007 | 30 Mar 2007 (F2007L00713) | 31 Mar 2007 | — |
| 50, 2007 | 30 Mar 2007 (F2007L00851) | 31 Mar 2007 | — |
| 51, 2007 | 30 Mar 2007 (F2007L00848) | 31 Mar 2007 | — |
| 52, 2007 | 30 Mar 2007 (F2007L00712) | 31 Mar 2007 | — |
| 125, 2007 | 24 May 2007 (F2007L01465) | 25 May 2007 | — |
| 265, 2007 | 7 Sept 2007 (F2007L03535) | 8 Sept 2007 | — |
| 266, 2007 | 7 Sept 2007 (F2007L03537) | 8 Sept 2007 | — |
| 267, 2007 | 7 Sept 2007 (F2007L03536) | 8 Sept 2007 | — |
| 290, 2007 | 27 Sept 2007 (F2007L03752) | 28 Sept 2007 | — |
| 160, 2008 | 8 Aug 2008 (F2008L02843) | 9 Aug 2008 | — |
| 161, 2008 | 8 Aug 2008 (F2008L02845) | 9 Aug 2008 | — |
| 162, 2008 | 8 Aug 2008 (F2008L02844) | 9 Aug 2008 | — |
| 218, 2008 | 31 Oct 2008 (F2008L03611) | 1 Nov 2008 | — |
| 219, 2008 | 31 Oct 2008 (F2008L03612) | 1 Nov 2008 | — |
| 220, 2008 | 31 Oct 2008 (F2008L03610) | 1 Nov 2008 | — |
| 34, 2009 | 13 Mar 2009 (F2009L00835) | 14 Mar 2009 | — |
| 35, 2009 | 13 Mar 2009 (F2009L00834) | 14 Mar 2009 | — |
| 36, 2009 | 13 Mar 2009 (F2009L00838) | 14 Mar 2009 | — |
| 37, 2009 | 13 Mar 2009 (F2009L00837) | 14 Mar 2009 | — |
| 38, 2009 | 13 Mar 2009 (F2009L00836) | 14 Mar 2009 | — |
| 39, 2009 | 13 Mar 2009 (F2009L00833) | 14 Mar 2009 | — |
| 77, 2009 | 15 May 2009 (F2009L01297) | 16 May 2009 | — |
| 124, 2009 | 25 June 2009 (F2009L02476) | never commenced  (SLI No 176, 2009) | — |
| 125, 2009 | 25 June 2009 (F2009L02471) | never commenced  (SLI No 176, 2009) | — |
| 126, 2009 | 25 June 2009 (F2009L02477) | never commenced  (SLI No 176, 2009) | — |
| 127, 2009 | 25 June 2009 (F2009L02478) | never commenced  (SLI No 176, 2009) | — |
| 208, 2009 | 21 Aug 2009 (F2009L03208) | 22 Aug 2009 | — |
| 212, 2009 | 7 Sept 2009 (F2009L03396) | 8 Sept 2009 | — |
| 213, 2009 | 7 Sept 2009 (F2009L03397) | 8 Sept 2009 | — |
| 214, 2009 | 7 Sept 2009 (F2009L03398) | 8 Sept 2009 | — |
| 215, 2009 | 7 Sept 2009 (F2009L03399) | 8 Sept 2009 | — |
| 219, 2010 | 21 July 2010 (F2010L02093) | 22 July 2010 | — |
| 220, 2010 | 21 July 2010 (F2010L02094) | 22 July 2010 | — |
| 221, 2010 | 21 July 2010 (F2010L02095) | 22 July 2010 | — |
| 222, 2010 | 21 July 2010 (F2010L02096) | 27 Nov 2010 (r 2) | — |
| 252, 2010 | 28 Oct 2010 (F2010L02825) | 29 Oct 2010 | — |
| 253, 2010 | 28 Oct 2010 (F2010L02826) | 29 Oct 2010 | — |
| 254, 2010 | 28 Oct 2010 (F2010L02828) | 29 Oct 2010 | — |
| 45, 2011 | 8 Apr 2011 (F2011L00586) | 9 Apr 2011 | — |
| 22, 2012 | 9 Mar 2012 (F2012L00553) | 10 Mar 2012 | — |
| 23, 2012 | 9 Mar 2012 (F2012L00554) | 10 Mar 2012 | — |
| 24, 2012 | 9 Mar 2012 (F2012L00555) | 10 Mar 2012 | — |
| 25, 2012 | 9 Mar 2012 (F2012L00556) | 10 Mar 2012 | — |
| 40, 2012 | 5 Apr 2012 (F2012L00796) | 9 Apr 2012 | — |
| 59, 2012 | 11 May 2012 (F2012L01016) | 12 May 2012 | — |
| 191, 2012 | 17 Aug 2012 (F2012L01693) | 18 Aug 2012 | — |
| 192, 2012 | 17 Aug 2012 (F2012L01694) | 18 Aug 2012 | — |
| 193, 2012 | 17 Aug 2012 (F2012L01695) | 18 Aug 2012 | — |
| 194, 2012 | 17 Aug 2012 (F2012L01696) | 18 Aug 2012 | — |
| 195, 2012 | 17 Aug 2012 (F2012L01697) | 18 Aug 2012 | — |
| 66, 2013 | 23 May 2013 (F2013L00825) | 28 May 2013 (s 2) | — |
| 160, 2013 | 11 July 2013 (F2013L01353) | 12 July 2013 (s 2) | — |
| 161, 2013 | 11 July 2013 (F2013L01357) | 12 July 2013 (s 2) | — |
| 162, 2013 | 11 July 2013 (F2013L01358) | 12 July 2013 (s 2) | — |
| 163, 2013 | 11 July 2013 (F2013L01354) | 12 July 2013 (s 2) | — |
| 164, 2013 | 11 July 2013 (F2013L01356) | 12 July 2013 (s 2) | — |
| 165, 2013 | 11 July 2013 (F2013L01355) | 12 July 2013 (s 2) | — |
| 241, 2013 | 25 Nov 2013 (F2013L01969) | 26 Nov 2013 (s 2) | — |
| 47, 2014 | 16 May 2014 (F2014L00550) | 17 May 2014 (s 2) | — |
| 117, 2014 | 5 Aug 2014 (F2014L01073) | 6 Aug 2014 (s 2) | — |
| 6, 2015 | 2 Mar 2015 (F2015L00234) | 3 Mar 2015 (s 2) | — |
| 7, 2015 | 2 Mar 2015 (F2015L00235) | 3 Mar 2015 (s 2) | — |
| 8, 2015 | 2 Mar 2015 (F2015L00233) | 3 Mar 2015 (s 2) | — |
| 9, 2015 | 2 Mar 2015 (F2015L00236) | 3 Mar 2015 (s 2) | — |
| 57, 2015 | 1 May 2015 (F2015L00621) | 2 May 2015 (s 2) | — |
| 126, 2015 | 10 Aug 2015 (F2015L01237) | 11 Aug 2015 (s 2(1) item 1) | — |
| 127, 2015 | 10 Aug 2015 (F2015L01238) | 11 Aug 2015 (s 2(1) item 1) | — |
| 128, 2015 | 10 Aug 2015 (F2015L01236) | 11 Aug 2015 (s 2(1) item 1) | — |
| 129, 2015 | 10 Aug 2015 (F2015L01235) | 11 Aug 2015 (s 2(1) item 1) | — |
| 130, 2015 | 10 Aug 2015 (F2015L01239) | 11 Aug 2015 (s 2(1) item 1) | — |
| 250, 2015 | 14 Dec 2015 (F2015L01993) | 15 Dec 2015 (s 2(1) item 1) | — |

| Name | Registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| Criminal Code Amendment (Control Orders—Legal Representation for Young People) Regulations 2017 | 30 June 2017 (F2017L00843) | 1 July 2017 (s 2(1) item 1) | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Part 1** |  |
| Part 1 heading | ad No 248, 2002 |
| r 2 | rep LA s 48D |
| r 3 | am No 265, 2007; No 250, 2015; F2017L00843 |
| **Part 2** |  |
| Part 2 | ad No 248, 2002 |
| **Division 1** |  |
| Division 1 | ad F2017L00843 |
| r 3A | ad F2017L00843 |
| r 3B | ad F2017L00843 |
| r 3C | ad F2017L00843 |
| **Division 2** |  |
| Division 2 heading | ad F2017L00843 |
| r 4 | ad No 248, 2002 |
|  | rs No 184, 2003 |
|  | am No 285, 2003; No 85, 2005; No 86, 2005; No 87, 2005; No 88, 2005 |
|  | rep No 298, 2005 |
|  | ad No 178, 2006 |
|  | am No 280, 2006 |
| r 4A | ad No 283, 2004 |
|  | rs No 220, 2006; No 160, 2008; No 219, 2010 |
|  | rep No 161, 2013 |
| r 4B | ad No 284, 2004 |
|  | rs No 221, 2006; No 161, 2008; No 220, 2010 |
|  | rep No 165, 2013 |
| r 4C | ad No 311, 2004 |
|  | rs No 276, 2006; No 218, 2008; No 253, 2010 |
|  | rep No 160, 2013 |
| r 4D | ad No 312, 2004 |
|  | rs No 277, 2006; No 220, 2008; No 252, 2010 |
|  | rep No 164, 2013 |
| r 4E | ad No 313, 2004 |
|  | rs No 278, 2006 |
|  | rep No 191, 2012 |
| r 4F | ad No 314, 2004 |
|  | rs No 279, 2006; No 162, 2008; No 221, 2010 |
|  | rep No 163, 2013 |
| r 4G | ad No 23, 2005 |
|  | rs No 3, 2007; No 219, 2008; No 254, 2010 |
|  | rep No 162, 2013 |
| r 4H | ad No 36, 2005 |
|  | rs No 39, 2007; No 34, 2009; No 22, 2012 |
|  | rep No 6, 2015 |
| r 4I | ad No 60, 2005 |
|  | rs No 47, 2007; No 35, 2009 |
|  | rep No 191, 2012 |
| r 4J | ad No 58, 2005 |
|  | rs No 48, 2007; No 39, 2009; No 23, 2012 |
|  | rep No 7, 2015 |
| r 4K | ad No 57, 2005 |
|  | rs No 52, 2007; No 36, 2009; No 24, 2012 |
|  | rep No 8, 2015 |
| r 4L | ad No 61, 2005 |
|  | rs No 49, 2007; No 38, 2009; No 25, 2012 |
|  | rep No 9, 2015 |
| r 4M | ad No 59, 2005 |
|  | rs No 50, 2007 |
|  | rep No 191, 2012 |
| r 4N | ad No 62, 2005 |
|  | rs No 51, 2007; No 37, 2009 |
|  | rep No 191, 2012 |
| r 4P | ad No 88, 2005 |
|  | rep No 214, 2005 |
| r 4Q | ad No 85, 2005 |
|  | rs No 125, 2007; No 77, 2009; No 59, 2012 |
|  | rep No 57, 2015 |
| r 4R | ad No 86, 2005 |
|  | rep No 214, 2005 |
| r 4S | ad No 87, 2005 |
|  | rep No 214, 2005 |
| r 4T | ad No 214, 2005 |
|  | rs No 265, 2007; No 212, 2009; No 194, 2012 |
|  | rep No 130, 2015 |
| r 4U | adNo 214, 2005 |
|  | rs No 266, 2007; No 213, 2009; No 191, 2012 |
|  | rep No 128, 2015 |
| r 4V | ad No 214, 2005 |
|  | rs No 267, 2007; No 214, 2009; 2012 No 192, 2012 |
|  | rep No 127, 2015 |
| r 4W | ad No 298, 2005 |
|  | rs No 290, 2007; No 215, 2009; No 195, 2012  rep No 126, 2015 |
| r 4X | ad No 208, 2009 |
|  | rs No 193, 2012 |
|  | rep No 129, 2015 |
| r 4Y | ad No 222, 2010 |
|  | rep No 241, 2013 |
| **Part 3** |  |
| Part 3 heading | rs No 66, 2013 |
| Division 3.1 heading | ad No 66, 2013 |
|  | rs and renum F2017L00843 |
| **Division 1** |  |
| Division 1 heading (prev Division 3.1 heading) |  |
| Part 3 | ad No 30, 2003 |
| r 5AA | ad No 45, 2011 |
|  | rep No 40, 2012 |
| r 5AB | ad No 45, 2011 |
|  | rep No 40, 2012 |
| r 5AC | ad No 45, 2011 |
|  | rep No 40, 2012 |
| r 5 | ad No 30, 2003 |
| Division 3.2 | ad No 66, 2013 |
| Division 3.2 heading | rs and renum F2017L00843 |
| **Division 2** |  |
| Division 2 heading (prev Division 3.2 heading) |  |
| r. 5A | ad No 66, 2013 |
| r. 5B | ad No 66, 2013 |
| r. 5C | ad No 66, 2013 |
| r. 5D | ad No 66, 2013 |
| r. 5E | ad No 66, 2013 |
| r. 5F | ad No 66, 2013 |
| Division 3.3 | ad No 250, 2015 |
| Division 3.3 heading | rs and renum F2017L00843 |
| **Division 3** |  |
| Division 3 heading (prev Division 3.3 heading) |  |
| r 5G | ad No 250, 2015 |
| r 5H | ad No 250, 2015 |
| **Part 4** |  |
| Part 3 heading | ad No 248, 2002 |
| Part 4 heading (prev Part 3) | renum No 30, 2003 |
| r 5 (prev r 4) | renum No 248,2002 |
| r 6 (prev r 5) | renum No 30, 2008 |
| **Part 5** |  |
| Part 5 | ad F2017L00843 |
| r 7 | ad F2017L00843 |
| **Schedule 1** |  |
| Schedule 1 | ad 2002 No 248 |
|  | am No 249, 2002; No 250, 2002; No 269, 2002; No 270, 2002; No 271, 2002; No 272, 2002; No 43, 2003; No 59, 2003; No 60, 2003; No 61, 2003; No 62, 2003; No 63, 2003; No 64, 2003; No 83, 2004; No 283, 2004; No 284, 2004; No 311, 2004; No 312, 2004; No 313, 2004; No 314, 2004; No 36, 2005; No 57, 2005; No 58, 2005; No 59, 2005; No 60, 2005; No 61, 2005; No 62, 2005 |
|  | rep No 88, 2005 |
|  | ad No 178, 2006 |
|  | am No 280, 2006 |
| Schedule 1A heading | rs No 285, 2003 |
|  | rep No 298, 2005 |
|  | ad No 45, 2011 |
|  | rep No 40, 2012 |
| Schedule 1A | ad No 184, 2003 |
|  | rep No 298, 2005 |
|  | ad No 45, 2011 |
|  | rep No 40, 2012 |
| Part 1 heading | ad No 285, 2003 |
|  | rep No 85, 2005 |
|  | ad No 45, 2011 |
|  | rep No 40, 2012 |
| Part 1 | rep No 85, 2005 |
|  | ad No 45, 2011 |
|  | rep No 40, 2012 |
| Part 2 | ad No 285, 2003 |
|  | rep No 86, 2005 |
|  | ad No 45, 2011 |
|  | rep No 40, 2012 |
| Part 3 | ad No 285, 2003 |
|  | rep No 87, 2005 |
|  | ad No 45, 2011 |
|  | rep No 40, 2012 |
| Part 4 | ad No 45, 2011 |
|  | rep No 40, 2012 |
| **Schedule 2** |  |
| Schedule 2 | ad No 30, 2003 |
| **Schedule 3** |  |
| Schedule 3 | ad No 66, 2013 |
|  | am No 62, 2014 |
| **Schedule 4** |  |
| Schedule 4 | ad No 66, 2013 |
|  | am No 47, 2014 |